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a b s t r a c t
Endothelin-converting enzyme-1 (Ece-1), a crucial component of the Endothelin signaling pathway, is
required for embryonic development and is an important regulator of vascular tone, yet the transcrip-
tional regulation of the ECE1 gene has remained largely unknown. Here, we deﬁne the activity and
regulation of an enhancer from the human ECE1 locus in vivo. The enhancer identiﬁed here becomes
active in endothelial progenitor cells shortly after their initial speciﬁcation and is dependent on a
conserved FOX:ETS motif, a composite binding site for Forkhead transcription factors and the Ets
transcription factor Etv2, for activity in vivo. The ECE1 FOX:ETS motif is bound and cooperatively
activated by FoxC2 and Etv2, but unlike other described FOX:ETS-dependent enhancers, ECE1 enhancer
activity becomes restricted to arterial endothelium and endocardium by embryonic day 9.5 in transgenic
mouse embryos. The ECE1 endothelial enhancer also contains an evolutionarily-conserved, consensus
SOX binding site, which is required for activity in transgenic mouse embryos. Importantly, the ECE1 SOX
site is bound and activated by Sox17, a transcription factor involved in endothelial cell differentiation and
an important regulator of arterial identity. Moreover, the ECE1 enhancer is cooperatively activated by the
combinatorial action of FoxC2, Etv2, and Sox17. Although Sox17 is required for arterial identity, few
direct transcriptional targets have been identiﬁed in endothelial cells. Thus, this work has important
implications for our understanding of endothelial speciﬁcation and arterial subspeciﬁcation.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Endothelin signaling is essential for embryonic development and
is an important regulator of vascular tone postnatally (Barton and
Yanagisawa, 2008; Kurihara et al., 1999). Endothelin signaling occurs
via two G protein-coupled receptors, ETA and ETB, which are bound
by Endothelin peptides and activate downstream intracellular
signaling to control many diverse cellular outputs (Barton and
Yanagisawa, 2008; Kedzierski and Yanagisawa, 2001). There are
three distinct Endothelin ligands, ET-1, ET-2, and ET-3, which
are encoded by three different genes and are initially produced as
larger pro-proteins (Barton and Yanagisawa, 2008; Kedzierski and
Yanagisawa, 2001). Preproendothelin proteins are cleaved by
ubiquitously expressed Furin proteases to produce a precursor of
Endothelin protein, referred to as Big Endothelin (Kido et al., 1997).
Big Endothelins are subsequently processed into the mature 21
amino acid ligands in a regulated process by either of two highly
speciﬁc proteases, Endothelin-converting enzyme (Ece)-1 or Ece-2
(Kedzierski and Yanagisawa, 2001). Inactivation of the Ece1 gene in
mice results in perinatal lethality and essentially phenocopies the
genetic loss of both Endothelin receptors in vivo (Yanagisawa et al.,
1998). In contrast, mice lacking Ece-2 protein appear grossly normal,
suggesting that Ece-2 plays a relatively more minor role in the
pathway and that the majority of Endothelin converting activity in
the embryo is mediated by Ece-1 (Yanagisawa et al., 2000).
Consistent with its critical role in Endothelin signaling, Ece-1 is
widely expressed during development and in adulthood (Yanagisawa
et al., 2000). In adults, Ece-1 is expressed in various organ systems
but is particularly prominent in the vascular endothelium (Korth
et al., 1999). In the developing mouse embryo, Ece1 is expressed
in multiple tissues, including the cardiovascular system (Yanagisawa
et al., 1998). Ece-1 function in the heart has been proposed to
be important in the formation of the cardiac conduction system
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(Hall et al., 2004; Takebayashi-Suzuki et al., 2000). Four Ece-1
isoforms have been described (Schweizer et al., 1997; Valdenaire et
al., 1999); the different ECE1 transcripts are initiated from distinct
transcriptional start sites, which results in slight variations in the N-
termini of the different proteins produced (Funke-Kaiser et al., 2000;
Li et al., 2012; Orzechowski et al., 1997; Valdenaire et al., 1999).
However, how ECE1 is controlled transcriptionally remains incom-
pletely understood. Some analyses of proximal promoter elements in
cell culture-based studies have been described (Funke-Kaiser et al.,
2000; Li et al., 2012; Orzechowski et al., 1998; Orzechowski et al.,
1997; Valdenaire et al., 1999), but the regulation of the ECE1 gene
in vivo has not been addressed previously.
The Sox family of high mobility group (HMG) transcription
factors is important for development (Kamachi and Kondoh, 2013).
In particular, members of the SoxF subfamily, Sox7, Sox17, and
Sox18, are key regulators of endothelial cell development and
differentiation (Francois et al., 2010). Sox7 is an important reg-
ulator of vascular development (Costa et al., 2012; Wat and
Wat, 2014). Sox18 is a key regulator of venous and lymphatic
development and functions in a partially redundant manner with
Sox7 (Francois et al., 2008; Tammela and Alitalo, 2010). Sox17,
which is widely appreciated for its role in endoderm development
(Hudson et al., 1997; Tam et al., 2003), is also a critical regulator of
endothelial gene expression and arterial development (Choi et al.,
2012; Corada et al., 2013; Sakamoto et al., 2007). Endothelial-
speciﬁc deletion of Sox17 in the mouse results in embryonic
demise with defects in vascular remodeling and an apparent
failure to form major arteries (Corada et al., 2013; Kim et al.,
2007; Lee et al., 2014). Though it is clear that SoxF factors are key
regulators of endothelial development, few direct endothelial
targets have been identiﬁed to date.
The Ets transcription factor Etv2 is a central regulator of
endothelial cell speciﬁcation (Lammerts van Bueren and Black,
2012; Meadows et al., 2011). Inactivation of the Etv2 gene in mice
results in loss of the endothelial and hematopoietic lineages
(Ferdous et al., 2009; Lee et al., 2008). Similarly, morpholino
knock down of the Etv2 ortholog etsrp in zebraﬁsh results in
profound defects in vascular development (De Val et al., 2008;
Sumanas and Lin, 2006). Co-expression of Etv2 and the Forkhead
transcription factor FoxC2 results in dramatic cooperative activa-
tion of Etv2-dependent endothelial genes (De Val et al., 2008).
Numerous endothelial genes may be direct transcriptional targets
of Etv2 and FoxC2 via a composite DNA binding element, referred
to as the FOX:ETS motif (De Val et al., 2008). Previously, we
identiﬁed over 1500 evolutionarily-conserved FOX:ETS motifs
associated with approximately 1200 endothelial genes in the
human genome (De Val et al., 2008). Among the putative enhan-
cers identiﬁed in that prior study was a small element from the
human ECE1 gene (De Val et al., 2008). Indeed, a preliminary test
of the ECE1 element in a transient transgenic mouse embryo assay
found that it functioned as an endothelial-speciﬁc enhancer at
embryonic day (E) 9.5 (De Val et al., 2008).
In the present study, we characterized the activity and regulation
of the ECE1 endothelial-speciﬁc enhancer in detail. We found that the
ECE1 enhancer was active in early endothelial progenitors and then
rapidly restricted only to arterial endothelium and endocardium. We
also found that enhancer activity was dependent on the previously
predicted FOX:ETS motif, which we found was a bona ﬁde element for
cooperative activation by FoxC2 and Etv2. In addition, we show that
the enhancer is dependent on an evolutionarily-conserved SOX site,
which is bound and activated by the arterially-restricted Sox factor
Sox17. Finally, we show that the Sox17, Etv2, and FoxC2 cooperatively
activate the ECE1 endothelial enhancer. Thus, these studies deﬁne the
ﬁrst bona ﬁde in vivo enhancer of ECE1 transcription, identify a direct
arterial-speciﬁc target of Sox17, and establish cooperativity of Sox17
with other core endothelial transcription factors.
Materials and methods
Plasmids, cloning, and mutagenesis
FoxC2 and Etv2 expression vectors have been described pre-
viously (De Val et al., 2008). The mouse Sox17 cDNA was
subcloned from the previously described plasmid pCIG-Sox17
(Sinner et al., 2007) into the pRK5 expression vector (Clontech)
using the XhoI restriction site to create plasmid pRK5-Sox17. The
reporter plasmid pTK-β-gal has been brieﬂy described previously
(Schachterle et al., 2012; Verzi et al., 2007) and contains a minimal
promoter from the Herpes Simple virus thymidine kinase gene,
sufﬁcient to activate expression in cell culture and competent to
respond to neighboring enhancer sequences when inserted into
the vector, upstream of a lacZ reporter gene. ECE1[623]-lacZ has
also been brieﬂy described previously: a fragment from the human
ECE1 locus was PCR ampliﬁed using the following primers:
50-cataatcccggggcaaaaacacgcga-30 and 50-tgactgacccgggccagacat-
cacc-30, and the resulting 623 bp product was inserted into the
transgenic reporter plasmid hsp68‐lacZ vector after XmaI digest
(De Val et al., 2008). For cell culture experiments, a shorter, 164 bp
region of the ECE1 enhancer encompassing the core enhancer was
PCR ampliﬁed using the following primers: 50-cataatcccgggg-
caaaaacacgcga-30 and 50-attgctgctggcagatctgtccct-30. The resulting
amplicon was digested with BglII and was then ligated into the
BglII and BamHI restriction sites in the pTK-β-gal reporter plasmid
to create plasmid ECE1-TK-β-gal. Mutations were introduced
into the ECE1 enhancer sequence by PCR as described (Dodou et
al., 2003) to create the following mutant sequences: mutant
FOX:ETS motif (mFEM), 50-tagctaatgaggcagggaggcacaat-30; mSOX,
50-ggaagggaggcaggtagagaggaagt-30. For the SOX site/FOX:ETS motif
double mutant (mF/mS), the SOX site was mutated in the mFEM
context using the same mutagenic primers.
Generation of transgenic mice
Transgene fragments were gel puriﬁed away from the par-
ental plasmid backbone, prepared, and injected into oocytes by
pronuclear injection as previously described (Dodou et al.,
2003). The presence of a lacZ transgene in embryo yolk sacs or
tail biopsies was determined by Southern blot or by PCR using
the following primers: 50-ctgttccaagagatgcttcctg-30 and 50-
ctcagtttggatgttcctggag-30. All experiments using animals were
reviewed and approved by the UCSF Institutional Animal Care
and Use Committee and complied with all institutional and
federal guidelines.
X-gal staining and immunoﬂuorescence
X-gal staining for detection of β-galactosidase and counterstaining
with Nuclear Fast Red were conducted as described previously
(Anderson et al., 2004). For section immunoﬂuorescence, embryos
were sectioned, dewaxed, boiled in antigen retrieval solution
(Biogenex), and blocked in PBS containing 10% sheep serum and
0.1% Triton X-100. The following primary antibodies were used at
1:100 dilutions in blocking serum: goat anti-ECE1 (R&D AF1784), goat
anti-Nrp1 (R&D AF566), goat-anti Nrp2 (R&D AF2215), goat anti-
connexin40 (Santa Cruz sc-20466), mouse anti-COUP-TFII (Perseus
Proteomics PP-H7147-00), and chicken anti-β-galactosidase (Abcam
ab9361). The following secondary antibodies were used: rabbit anti-
goat 594 (Invitrogen A11080), rabbit anti-chicken 488 (Jackson
ImmunoResearch 303–545-003), and rabbit anti-mouse 594 (Invitro-
gen A11062). Slides were mounted and photographed as described
previously (Rojas et al., 2009).
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Cell culture, transfection, and reporter assays
Cos-1 cells were maintained in Dulbecco modiﬁed Eagle
medium (DMEM) supplemented with 10% fetal bovine serum, 1%
L-glutamine, and 1% penicillin-streptomycin. Transfections were
performed with Fugene6 (Roche) according to manufacturers
instructions; transfection mixes contained 350 ng of reporter
construct and 450 ng of total expression vectors. The total
amount of transfected plasmid DNA was held constant in all
cases. Cells were harvested 48 h after transfection, and β-
galactosidase activity was determined using the Luminescent
β-gal Detection Kit II (Clontech). Relative light units were
normalized to total protein as measured by Bradford Assay
(Bio-Rad).
Electrophoretic mobility shift assay (EMSA)
DNA binding assays were performed using modiﬁed 1
binding buffer (40 mM KCl, 15 mM HEPES pH 7.9, 1 mM EDTA,
0.5 mM DTT, 50% glycerol) as described previously (Dodou et al.,
2003). Recombinant proteins were made using the Promega
TNT Coupled Reticulocyte System according to manufacturer's
instructions. Full length FoxC2, Etv2, and Sox17 were expressed
from their respective pRK5 vectors using SP6 polymerase.
Control and mutated control probe sequences for FOX:ETS motif
from the Mef2c gene and for the SOX site from the mouse
laminin 1α gene have each been described previously (De Val et
al., 2008; Niimi et al., 2004). ECE1 probes were designed with
guanine overhangs for labeling with Klenow and 32P-dCTP.
The sense strand sequences for the probes were: ECE1_FOX:ETS,
50-gggagtctagctaaacaggaagggaggcacaatgagagga-30; ECE1_mFEM,
50-gggagtctagctaatgaggcagggaggcacaatgagagga-30; ECE1_SOX,
50-ggaagggaggcacaatgagaggaagt-30-; ECE1_mSOX, 50-ggaagggag-
gcaggtagagaggaagt-30.
Results
ECE1 enhancer activity is restricted to arterial endothelium
Previously, we cloned a 623-bp fragment of human genomic
sequence (ECE1[623]) located 384 bp upstream of one of the three
transcriptional start sites for the ECE1 gene (Fig. 1A; and De Val
et al., 2008). This fragment contains the predicted FOX:ETS motif,
and we previously established that this element functioned as an
endothelial-speciﬁc transcriptional enhancer in transgenic mouse
embryos at a single time point (De Val et al., 2008). To facilitate a
more complete analysis of this regulatory element, we generated
stable transgenic lines and analyzed enhancer activity in embryos
from E7.5 to E18.5 (Fig. 2, and data not shown).
The ECE1 endothelial enhancer ﬁrst demonstrated activity in vivo
beginning at E7.75 (Fig. 2A). At this stage, X-gal staining was
apparent in cells within the lateral plate mesoderm (Fig. 2A), where
vascular endothelial progenitors in the embryo proper originate
(Patan, 2004). β-galactosidase activity was also evident more ante-
riorly in pre-cardiac mesoderm (Fig. 2A). By E8.5, X-gal staining was
clearly visible in the paired dorsal aortae in the trunk and within the
nascent endocardium in the heart (Fig. 2B). Following the onset of
sprouting angiogenesis at approximately E9.0, ECE1 enhancer activ-
ity could be readily observed throughout the vasculature, including
in intersegmental vessels (Fig. 2C). Within the heart, reporter
activity was restricted to the endocardium at E9.0 (Fig. 2C,D). At
E9.5, activity of the ECE1 enhancer was widely apparent in the
vascular endothelium (Fig. 2E), but activity appeared to be restricting
to arterial endothelium and endocardium, as X-gal staining was
robust in arteries and very weak in developing veins (Fig. 2F).
Enhancer activity remained robust in arterial endothelium through-
out the remainder of mouse embryonic development. At E12.5,
β-galactosidase expression remained completely restricted to arter-
ial endothelium and endocardium (Fig. 2G,H).
SV40 polyAlacZHSP68ECE1[623]-lacZ
100%
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Fig. 1. A conserved, endothelial-speciﬁc enhancer in the ECE1 locus. (A) VISTA plot comparing human and mouse sequence within the ECE1 locus (upper schematic). Human
sequence from hg19 (Build GRCh37.p13, Chr1: 21606465–21606628) was used as the reference sequence. CNS, conserved, non-coding sequence; UTR, untranslated exon
sequence. A 623-bp fragment encompassing the CNS containing the FOX:ETS motif was cloned upstream of the hsp68 minimal promoter for expression of β-galactosidase
(lower panel). (B) ClustalW multiple sequence alignment of the core 164-bp ECE1 enhancer region from human, mouse, and opossum. Conserved nucleotides are indicated
with asterisks. The conserved FOX:ETS motif, a second conserved ETS site, and the conserved SOX site are indicated.
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To examine the activity of the ECE1 enhancer in more detail, we
compared β-galactosidase expression from the ECE1 reporter to the
expression of endogenous Ece-1 protein in arteries and veins and to
artery and vein-speciﬁc markers by co-immunoﬂuorescence at E12.5
(Fig. 3). We found that endogenous Ece-1 was expressed throughout
the endothelium in both arteries and veins (Fig. 3A). In contrast,
β-galactosidase expression was detectable exclusively in arteries
(Fig. 3A'). The overlap of β-galactosidase and endogenous Ece-1 only
in arteries (Fig. 3A″) suggests that the ECE1 enhancer described here
controls only a subset of the endogenous expression pattern.
Expression of the arterial markers Neuropilin-1 and Connexin40
(Buschmann et al., 2010; Herzog et al., 2001) overlapped completely
with β-galactosidase expression (Fig. 3B,C), conﬁrming the activity of
the ECE1 enhancer in arterial endothelium. Likewise, comparison
of β-galactosidase expression with the expression of the venous
markers Neuropilin-2 and COUP-TFII (Chong et al., 2011; Herzog
et al., 2001; You et al., 2005) also conﬁrmed the arterial restriction of
ECE1 enhancer activity since β-galactosidase expression did not
overlap with expression of the venous markers (Fig. 3D,E). Taken
together, the results presented in Figs. 2 and 3 establish that ECE1
[623] is an arterial-restricted enhancer in vivo.
FoxC2 and Etv2 regulate the ECE1 arterial enhancer
Although the ECE1 enhancer was originally identiﬁed based on
the presence of a conserved FOX:ETS motif (De Val et al., 2008), the
predicted FOX:ETS motif in the enhancer has not been previously
validated as a bona ﬁde binding site for FoxC2 and Etv2. Therefore,
we performed electrophoretic mobility shift assays (EMSA) with
recombinant FoxC2 and Etv2 proteins (Fig. 4A and B, respectively).
Both factors efﬁciently bound to the ECE1 FOX:ETS motif (Fig. 4A,B,
lane 2 in each panel). Unlabeled oligonucleotide probes representing
a control FOX:ETS motif from an endothelium-speciﬁc enhancer of
the mouse Mef2c gene and the ECE1 FOX:ETS motif itself efﬁciently
competed for binding (Fig. 4A,B, lanes 3 and 5 in each panel). In
contrast, mutant versions of each FOX:ETS motif failed to compete
for binding even when present in 100-fold excess (Fig. 4A,B, lanes
4 and 6 in each panel). Taken together, the results of the EMSA
establish that the FOX:ETS motif in the ECE1 enhancer is a bona ﬁde
in vitro binding element recognized by FoxC2 and Etv2.
To further test whether the FOX:ETS motif in the ECE1 arterial
enhancer is a functional element for FoxC2 and Etv2, we tested the
ability of FoxC2 and Etv2 to transactivate the core region of
the ECE1 enhancer (Fig. 4C). FoxC2 alone signiﬁcantly activated
the ECE1-TK-β-gal reporter (Fig. 4C, compare lanes 1 and 3;
p¼0.0043). This activation was dependent on an intact FOX:ETS
motif since mutation completely abolished FoxC2-dependent
transactivation (Fig. 4C, compare lanes 3 and 4). Similarly, Etv2
also signiﬁcantly activated the ECE1 reporter (Fig. 4C, compare
lanes 1 and 5; p¼0.0100) and this activation was also dependent
on an intact FOX:ETS motif (Fig. 4C, compare lanes 5 and 6).
Importantly, and consistent with previous studies of other
FoxC2/Etv2-dependent enhancers (De Val et al., 2008), co-transfec-
tion of FoxC2 and Etv2 expression constructs with the ECE1-TK-β-gal
reporter resulted in strong (440-fold) activation of the ECE1
enhancer compared to control (Fig. 4C, compare lanes 1 and 7;
po0.001). Mutation of the FOX:ETS motif nearly abolished reporter
activation (Fig. 4C, compare lanes 7 and 8). The cooperative activation
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Fig. 2. The ECE1 enhancer is endothelial-speciﬁc and restricts to arterial endothelium. ECE1[623]-lacZ transgenic embryos were collected at E7.75 (A), E8.5 (B), E9.0 (C,D),
E9.5 (E,F) and E12.5 (G,H) and were X-gal stained and then analyzed by whole mount (A,B,C,E,G) or were sectioned and counterstained (D,F,H) to analyze ECE1 enhancer
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100 mm.
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Fig. 3. ECE1 enhancer activity is restricted to arterial endothelium at E12.5. Immunostaining of transverse sections through the trunk region of ECE1[623]-lacZ transgenic
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Fig. 4. The ECE1 enhancer contains a bona ﬁde FOX:ETS motif. (A,B) EMSA using a radiolabeled double-stranded oligonucleotide probe encompassing the ECE1 FOX:ETS motif.
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(C) Cos-1 cells were co-transfected with pRK5 expression vector (lanes 1,2), pRK5-FoxC2 (lanes 3,4), pRK5-Etv2 (lanes 5,6), or pRK5-FoxC2 and pRK5-Etv2 (lanes7,8) and the
wild type [wt] ECE1-TK-β-gal reporter (lanes 1,3,5,7) or a version of the reporter with a mutated FOX:ETS motif [mFEM] (lanes 2,4,6,8) and assayed for β-galactosidase
activity. FoxC2 and Etv2 each activated the reporter (lanes 3,5). Cooperative activation was observed when FoxC2 and Etv2 were co-expressed (lane7). In all cases, activation
was dependent on an intact FOX:ETS motif. Data are expressed as the mean fold activation plus SEM for 3 independent transfections and analyses. (D,D0) Wild type [wt] ECE1
[623]-lacZ (D) or ECE1[623]-lacZ with a mutated FOX:ETS motif [mFEM] (D0) transgenic embryos were collected at E9.0 and were X-gal stained to detect β-galactosidase
activity. The wild type enhancer was active throughout the arterial vasculature (7/9 independent transgenic lines; 2 lines showed little or no expression). Mutation of the
FOX:ETS motif site completely abolished all activity in 3/3 independent transgenic lines examined. Representative transgenic embryos are shown. da, dorsal aorta; hrt, heart.
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of the reporter by both factors together represents a signiﬁcant
increase over the transactivation by either factor alone (po0.001
versus either FoxC2 or Etv2 alone). These data demonstrate that the
ECE1 endothelial enhancer is cooperatively regulated by FoxC2
and Etv2.
To determine if the ECE1 FOX:ETS motif was necessary for
reporter activity in vivo, we generated embryos with either wild
type ECE1[623]-lacZ or a mutant version with a disrupted FOX:ETS
motif and examined enhancer activity at E9.0 (Fig. 4D,D0). As
expected, X-gal staining demonstrated robust β-galactosidase activ-
ity in embryos harboring the wild transgene (Fig. 4D). In contrast,
embryos transgenic for the mutant transgene (mFEM) exhibited no
detectable X-gal staining (Fig. 4D0). These data demonstrate that the
ECE1 FOX:ETS is required for enhancer activity in vivo. Taken
together, the results of Fig. 4 support the idea that the ECE1
FOX:ETS motif is a bona ﬁde binding element for FoxC2 and Etv2
and is required for enhancer activation in vitro and in vivo.
A SOX binding site is essential for ECE1 enhancer activity
Comparison of ECE1 enhancer sequences from human, mouse,
and opossum in the core region of human:mouse conservation
revealed that only three short stretches of sequence are perfectly
conserved between the two placental mammals and the marsupial
opossum (Fig. 1B). Two of those elements are the FOX:ETS motif and
a neighboring ETS site. The only other perfectly conserved sequence
in the core enhancer is a consensus SOX site (Fig. 1B; and Hosking
et al., 1995; Niimi et al., 2004). This candidate site attracted our
attention given the essential role of the SoxF subfamily in vascular
endothelial development (Francois et al., 2010). In particular, Sox17
expression is restricted to arteries and has recently been described
to be a key regulator of arterial development (Corada et al., 2013).
Therefore, we reasoned that Sox17 might be a regulator of the ECE1
arterial-restricted enhancer via the consensus SOX site.
To determine whether the SOX motif in the ECE1 enhancer
might function as a Sox17 binding site, we performed EMSA with
recombinant Sox17 protein (Fig. 5A). Sox17 bound efﬁciently to the
ECE1 SOX motif (Fig. 5A, lane 2). Binding to the SOX site by Sox17
was speciﬁc since addition of excess unlabeled oligonucleotide
probe from a control Sox17 site from the laminin 1α gene
competed with the radiolabeled probe and prevented the shift
from occurring (Fig. 5A, lane 3). Similarly, binding of Sox17 to the
ECE1 SOX site was abolished by addition of an unlabeled double-
stranded oligonucleotide with the exact ECE1 SOX site sequence
(Fig. 5A, lane 5). Mutant versions of the control SOX site and the
ECE1 SOX site were unable to compete for binding even when
added at 100-fold excess (Fig. 5A, lanes 4 and 6, respectively).
These results establish that the consensus SOX motif in the ECE1
enhancer is a bona ﬁde binding site recognized by Sox17 in vitro.
We also tested the ability of Sox17 to transactivate the ECE1
enhancer (Fig. 5B). Co-transfection of a Sox17 expression vector
with the ECE1-TK-β-gal reporter resulted in a signiﬁcant increase
in reporter activity compared to the activation obtained with the
parent expression vector (Fig. 5B, compare lanes 1 and 3; 13-fold
activation, p¼0.0038). Mutation of the SOX site in the enhancer
signiﬁcantly reduced activity, although some residual reporter
activity remained (Fig. 5B, compare lanes 3 and 4; p¼0.0330).
The slight residual activity of the enhancer even with the mutant
SOX site may be due to the existence of nonconsensus binding
sites in the ECE1[164] core enhancer that allow for some activation
of the reporter to occur, or it may be due to indirect activation by
Sox17. Overall, however, the results presented in Fig. 5B demon-
strate that Sox17 is sufﬁcient for activation of the ECE1 enhancer,
and that this activation is mediated primarily by binding to the
conserved SOX site in the core enhancer.
We next asked if the SOX site was required for ECE1 enhancer
activity in vivo. To test this, we generated transgenic mouse embryos
harboring wild type ECE1[623]-lacZ and a mutant version with a
disrupted SOX site (Fig. 5C,C0). As described above, embryos trans-
genic for the wild type ECE1[623]-lacZ construct showed strong X-gal
staining in the vascular endothelium at E9.5 (Fig. 5C). In contrast, we
did not observe any staining in embryos carrying the mutant version
of the reporter construct (Fig. 5C0). Thus, the activity of the ECE1
enhancer in vivo is dependent on the SOX binding site.
Sox17, FoxC2, and Etv2 synergistically activate the ECE1 enhancer
The proximity of the FOX:ETS and SOX binding sites in the core
enhancer suggested the possibility that FoxC2, Etv2, and Sox17
might function cooperatively to activate the ECE1 enhancer. To test
this possibility, we examined the combined effects of these three
transcription factors on ECE1 enhancer transactivation (Fig. 6A). As
expected, FoxC2 and Etv2 exhibited strong cooperativity on the
ECE1 enhancer (Fig. 6A, lane 5). Importantly, co-expression of
Sox17 with either FoxC2 or Etv2 also resulted in synergistic
activation of the reporter (Fig. 6A, lanes 6 and 7). Co-expression
of all three factors resulted in even more robust activation of the
ECE1 reporter (4160-fold) than the activation observed with any
combination of two factors (Fig. 6A, lane 8). Taken together, these
observations suggest that Sox17 can function cooperatively with
Etv2 and FoxC2 separately or combinatorially to activate
endothelial-speciﬁc regulatory elements.
We next tested whether the FOX:ETS and SOX sites in the ECE1
enhancer were required for cooperative activation by FoxC2, Etv2,
and Sox17 (Fig. 6B). Mutation of either the FOX:ETS motif or the SOX
site dramatically reduced, but did not completely eliminate, transac-
tivation of the reporter by the three factors (Fig. 6B, lanes 2 and 3). In
contrast, simultaneous disruption of the FOX:ETS motif and the SOX
site completely abolished all reporter activity (Fig. 6B, lane 4). These
data establish that maximal synergy by FoxC2, Etv2, and Sox17
requires the presence of functional binding sites for each factor.
Discussion
Modular regulation of ECE1 transcription
Ece-1 functions as an important regulatory node in Endothelin
signaling by controlling the production of the mature Endothelin
peptide (Turner and Murphy, 1996). In spite of its importance in
embryonic development and in the control of vascular tone
postnatally, the transcriptional regulation of ECE1 has not been
extensively investigated. In the present study, we conducted
the ﬁrst analysis of ECE1 transcriptional regulation using an
in vivo approach. Compared to endogenous Ece1, which is
expressed broadly in the developing mouse embryo, including
throughout the vasculature (Yanagisawa et al., 1998; and data not
shown), the ECE1 enhancer described here only marks a subset of
the endogenous gene expression pattern. This suggests that
additional enhancers regulate ECE1 in other parts of its expres-
sion domain. Modular regulation by multiple, distinct enhancers
is a recurrent mechanism for many developmental genes with
complex expression patterns, such as ECE1, and is thought to help
achieve precise temporal and spatial control of expression
(Spitz and Furlong, 2012).
Restriction of ECE1 enhancer activity to arterial endothelium
and endocardium
The ECE1 enhancer described here rapidly restricts to arterial
endothelium. However, at early times, activity appears to be
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Fig. 5. The ECE1 enhancer contains a bona ﬁde SOX site. (A) EMSA using a radiolabeled double-stranded oligonucleotide probe corresponding to the ECE1 SOX site.
Recombinant Sox17 bound to the probe (lane 2). Addition of excess unlabeled control SOX site [C] or the ECE1 SOX site [E] abolished binding (lanes 3,5). Unlabeled mutant
versions of the SOX sites [mC, mE] did not compete for Sox17 binding at 100-fold excess (lanes 4,6). Unprogrammed reticulocyte lysate is shown in lane 1. Free probe is
denoted. (B) Cos-1 cells were co-transfected with pRK5 expression vector (lanes 1,2) or with pRK5-Sox17 (lanes 3,4) and the wild type [wt] ECE1-TK-β-gal reporter (lanes 1,3)
or a version of the reporter with a mutated SOX site [mSOX] (lanes 2,4) and assayed for β-galactosidase activity. Sox17 strongly activated the reporter (lane 3) and this
activation was largely dependent on an intact SOX site (lane 4). Data are expressed as the mean fold activation plus SEM for 3 independent transfections and analyses. (C,C0)
Wild type [wt] ECE1[623]-lacZ (C) or ECE1[623]-lacZ with a mutated SOX site [mSOX] (C0) transgenic embryos were collected at E9.5 and were X-gal stained to detect
β-galactosidase activity. The wild type enhancer was active throughout the arterial vasculature (7/9 independent transgenic lines; 2 lines showed little or no expression).
Mutation of the SOX site completely abolished all activity in all 3/3 independent transgenic lines examined. Representative transgenic embryos are shown. da, dorsal aorta;
hrt, heart.
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present more broadly in the endothelium, including in veins or
possibly in their progenitors. This may be due to reporter expres-
sion in the endothelial progenitor population and the perdurance
of β-galactosidase in veins once they have formed. Alternatively, it
is possible that the enhancer remains active in presumptive veins
until the venous character of the vessel has been fully established.
This may suggest that a population of early endothelial cells may
be neither arterial nor venous and that the ECE1 enhancer is active
in these early cells, in addition to being active subsequently in
arterial endothelium.
The three SoxF family members, Sox7, Sox17, and Sox18 are each
expressed in endothelial cells, including in the arterial endothelium
(Francois et al., 2010; Young et al., 2006), but only Sox17 is thought to
restrict exclusively to arterial endothelium within the vasculature
(Corada et al., 2013; Liao et al., 2009). Consistent with this notion,
deletion of Sox17 speciﬁcally in vascular endothelium results in
arteriovenous malformations (Corada et al., 2013). Furthermore, an
arterial enhancer of Dll4 contains a SOX binding site that is crucial for
activity in arterial endothelium (Sacilotto et al., 2013). Our ﬁndings
are consistent with a role for Sox17 as a key regulator of arterial fate
and arterial gene expression; the evidence presented here suggests
that Sox17 is a bona ﬁde regulator of the ECE1 arterial enhancer.
However, we cannot rule out that other SoxF factors or other
transcription factors acting via the SOX consensus element may be
involved in ECE1 enhancer activity and contribute to its arterial
restriction during embryogenesis.
Notch signaling in the vascular endothelium is also restricted to
arteries and is crucial for arterial identity (Lawson et al., 2001;
Roca and Adams, 2007; Zhong et al., 2001). However, it is currently
unknown how many arterial genes are direct Notch signaling
targets. Recently, a binding site for RBPJ, a downstream effector of
Notch signaling, has been identiﬁed in the Dll4 arterial enhancer
(Sacilotto et al., 2013; Wythe et al., 2013), suggesting that Dll4 is a
direct Notch target. In contrast, the ECE1 arterial-restricted enhan-
cer described here does not contain any discernible RBPJ binding
sites (Fig. 1B), suggesting that arterial restriction of this enhancer
may occur independent of direct Notch activation. This ﬁnding
supports the idea that regulatory pathways upstream or parallel to
Notch may also be sufﬁcient for artery-restricted expression and is
consistent with some recent studies that suggest that Sox17
functions in arterial identity upstream or possibly independent
of Notch signaling (Clarke et al., 2013; Corada et al., 2013).
Conversely, other recent studies suggest that Notch functions
upstream of Sox17 (Lee et al., 2014). Thus, it will be important
for future studies to resolve the relationship between Notch
signaling and Sox17 and their respective roles in arterial identity.
Transcription factor interactions in the endothelial cell gene
regulatory network
Etv2 is essential for endothelial progenitor cell speciﬁcation
and is thought to be a central upstream regulator of the gene
regulatory network that establishes the endothelial cell phenotype
(De Val and Black, 2009; Lammerts van Bueren and Black, 2012).
The previous work has shown that Etv2 activity is dramatically
enhanced by cooperative interactions with other transcription
factors (De Val et al., 2008; Shi et al., 2014). We show here that
the ECE1 enhancer, like other previously described endothelial
enhancers (De Val et al., 2008), is cooperatively activated by FoxC2
and Etv2 through its conserved FOX:ETS motif. Importantly, we
found that Sox17 also functions cooperatively with Etv2 to activate
the ECE1 enhancer and that transactivation by all three factors,
FoxC2, Etv2, and Sox17, results in additional synergistic activation.
After the initial speciﬁcation of the endothelial lineage, Etv2
expression is rapidly extinguished (Ferdous et al., 2009; Kataoka
et al., 2011; Lee et al., 2008), whereas Sox17 becomes restricted to
the arterial compartment within the vasculature (Corada et al., 2013;
Liao et al., 2009). FoxC2 is expressed throughout the early vascular
endothelium and its expression persists in the vascular endothelium
(Seo et al., 2006). Our observation that Sox17 cooperates with FoxC2
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Fig. 6. Synergistic activation of the ECE1 enhancer by combinatorial expression of Sox17, FoxC2, and Etv2 requires binding to the cognate binding site for each factor. (A) Cos-
1 cells were transfected with the wild type ECE1-TK-β-gal reporter plasmid and various combinations of pRK5 expression plasmids for FoxC2, Etv2, and Sox17 and were
assayed for β-galactosidase activity. The amount (ng) of each transfected expression plasmid is indicated. Data are expressed as the mean fold activation of reporter co-
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activation by the three transactivators was only observed when both cis-acting elements were intact (lane 1). Data are expressed as the mean relative β-galactosidase activity
plus SEM for 3 independent transfections and analyses.
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without a requirement for Etv2 (Fig. 6A) is consistent with the
possibility that the combined activities of FoxC2 and Sox17 may
account for the continued activation of the ECE1 enhancer in
arteries, following initial enhancer activation by Etv2, possibly in
combination with Forkhead and SoxF factors. It is interesting to
speculate that this may represent a general model for early
endothelial gene activation in which Etv2 and its cofactors are
involved in the initiation of gene expression at early times in the
endothelial gene regulatory network. Subsequently, as Etv2 expres-
sion is rapidly switched off, other transcription factors function
combinatorially to maintain and restrict endothelial gene expression
to speciﬁc vascular compartments. It will be important to decipher
these transcription factor relationships in order to understand the
endothelial cell gene regulatory network more completely.
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